resectable gastric or gastroesophageal junction adenocarcinoma
Showing 1 - 2 of 2
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Trial (Cadonilimab, AK117, Oxaliplatin)
Not yet recruiting
- Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
- Cadonilimab
- +5 more
- (no location specified)
Jul 17, 2023
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Seoul (Docetaxel, Oxaliplatin, S-1 and Durvalumab,
Recruiting
- Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
- Docetaxel, Oxaliplatin, S-1 and Durvalumab
- Durvalumab and Tremelimumab
-
Seoul, Korea, Republic ofAsan Medical Center
Jun 1, 2020